In these exceptional responders, the risk of breast cancer recurrence is low with associated excellent 5‐year relapse free survival of 95% and 94% in patients with HER2+ and Triple Negative breast cancers, respectively.[11] These findings argue against the need for definitive surgery and directly challenge the current paradigm of surgical resection established for solid tumors. This evidence concerns the gene ERBB2 and breast cancer.